Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
infectious respiratory diseases
Biotech
Moderna touts 3 phase 1 data sets to bolster early vax work
Early-stage shots aimed at Epstein–Barr virus, norovirus and shingles could further solidify the biotech's infectious disease portfolio.
Max Bayer
Mar 27, 2024 3:21pm
Novo Nordisk Foundation sets up $260M vaccine initiative
Dec 18, 2023 11:14am
Sanger Institute launches virus sequencing initiative
Jan 13, 2023 7:35am
Pfizer nabs RSV biotech ReViral in quick $525M bolt-on
Apr 7, 2022 8:27am
Ex-FDA interim head Giroir returns to biotech to make antivirals
Feb 11, 2022 10:00am
Pfizer kick-starts phase 3 respiratory syncytial virus trial
Sep 3, 2021 7:18am
